STOCK TITAN

Sangamo Therapeutics, Inc. - $SGMO STOCK NEWS

Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: $SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sangamo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sangamo Therapeutics's position in the market.

Rhea-AI Summary
Sangamo Therapeutics announces acceptance of six abstracts for presentation at the 30th Annual Congress of the European Society of Gene & Cell Therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
Rhea-AI Summary
Sangamo Therapeutics to participate in Jefferies Cell & Genetic Medicine Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
conferences
-
Rhea-AI Summary
Sangamo Therapeutics reports Q2 2023 financial results and recent business highlights. They have executed several business development deals and made progress in their clinical programs. They announced research evaluation and option agreements with Prevail Therapeutics and Chroma Medicine. In their program highlights, they provided updates on Fabry Disease, Renal Transplant Rejection, Neurology Epigenetic Regulation Programs, and Hemophilia A. They also shared their Q2 financial results, including a consolidated net loss of $114.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
Rhea-AI Summary
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) to Release Q2 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
-
Rhea-AI Summary
Sangamo Therapeutics and Chroma Medicine have entered into a research evaluation, option, and license agreement to develop epigenetic medicines using zinc finger proteins (ZFPs). Chroma will evaluate Sangamo's ZFPs for collaboration targets outside of the central nervous system. If Chroma exercises its option, Sangamo will receive payments and royalties on any Chroma products incorporating the licensed ZFPs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
management
Sangamo Therapeutics, Inc.

Nasdaq:SGMO

SGMO Rankings

SGMO Stock Data

108.31M
165.08M
9.45%
49.93%
5.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
RICHMOND

About SGMO

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.